Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial | Cardiovascular Diabetology

by

  • Kobayashi M, Girerd N, Zannad F. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol Dial Transpl. 2024;39:1063–72.

    CAS 

    Google Scholar     

  • Morales J, Handelsman Y. Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82:161–70.

    PubMed 

    Google Scholar     

  • Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138:929–44.

    PubMed 

    Google Scholar     

  • Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    CAS 
    Source link

    Related posts:

    1. Stress hyperglycemia ratio and machine learning model for prediction of all-cause mortality in patients undergoing cardiac surgery | Cardiovascular Diabetology
    2. Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study | Cardiovascular Diabetology
    3. Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction | Cardiovascular Diabetology
    4. The association between anion gap and prognosis in patients myocardial infarction with congestive heart failure: a retrospective analysis of the MIMIC-IV database | International Journal of Emergency Medicine

    • Leave a Comment